Table 3.
VO2peak (mL/kg FFM/min) |
VO2peak (mL/kg BW/min) |
Delta efficiency (%) |
|
---|---|---|---|
Measure | n = 20 | n = 20 | n = 29 |
Fat mass index | −.24 (−.57 to .15) | −.55* (−.80 to −.14) | .30 (−.08 to .60) |
%BF | −.24 (−.57 to .15) | −.60** (−.82 to −.21) | .40* (.04 to .67) |
VATa | −.10 (−.52 to .36) | −.16 (−.56 to .30) | .16 (−.22 to .50) |
SATa | −.49* (−.77 to −.06) | −.68** (−.86 to −.34) | .11 (−.27 to .46) |
Systolic BP (mm Hg) | −.06 (−.49 to .39) | −.03 (−.47 to .42) | −.09 (−.44 to .29) |
Diastolic BP (mm Hg) | −.42 (−.73 to .03) | −.52* (−.78 to −.10) | −.03 (−.39 to .34) |
HOMA-IR | .12 (−.34 to .53) | .02 (−.43 to .46) | −.11 (−.46 to .27) |
LDL-C (mg/dL) | −.08 (−.51 to .38) | −.04 (−.47 to .41) | −.04 (−.40 to .33) |
HDL-C (mg/dL) | −.08 (−.51 to .38) | −.18 (−.58 to .29) | .17 (−.21 to .51) |
TRIG (mg/dL) | −.03 (−.47 to .42) | −.07 (−.50 to .38) | −.07 (−.43 to .30) |
hsCRP (mg/L) | .01 (−.43 to .45) | −.23 (−.61 to .24) | .39* (.03 to .66) |
Cardiometabolic risk score | −.09 (−.51 to .37) | −.16 (−.56 to .30) | −.03 (−.39 to .34) |
Abbreviations: BP, blood pressure; BW, body weight; CI, confidence interval; FFM, fat-free mass; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; SAT, subcutaneous adipose tissue; TRIG, triglycerides; VAT, visceral adipose tissue; VO2peak, peak aerobic capacity; %BF, percentage body fat.
Note: Bolded values reached statistical significance, at a level further defined by ** or *
P < .01
P < .05.
n = 18/27 due to poor quality MRI data in 2 participants.